(also known as Mitoglitazone) is an investigational drug originally developed to treat Type 2 diabetes. It is currently being explored for its potential to treat neurodegenerative diseases like Parkinson’s and Alzheimer’s.
: It showed significantly less volume expansion (fluid retention) and less weight gain.
As an investigational compound, MSDC-0160 is primarily sold for . It is typically found through chemical suppliers rather than standard pharmacies. msdc 0160 buy
: Phase 2a trials suggested it may help maintain glucose metabolism in brain regions associated with cognitive decline. Availability and Purchase Information
: Shown to reduce neuroinflammation and protect dopamine-producing neurons in animal models. (also known as Mitoglitazone) is an investigational drug
: It is a first-in-class "mTOT Modulator" that works by inhibiting the mitochondrial pyruvate carrier (MPC). Unlike older diabetes drugs, it is "PPARγ-sparing," meaning it aims to provide the same glucose-lowering benefits with fewer side effects like weight gain or fluid retention. Current Research Status :
In clinical trials, MSDC-0160 has been reported as generally well-tolerated. As an investigational compound, MSDC-0160 is primarily sold
While researchers and companies often list it for sale online, it is critical to note that for human use outside of clinical trials. Product Overview